Scinai Immunotherapeutics Ltd. - Understand $scni stock

$SCNI Market Cap: $2.768 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$284.0K

TTM

Gross Margin

-57.75%

TTM

Net Earnings

-$3.704M

TTM

Current Assets

$3.657M

Q2 2024

Current Liabilities

$1.672M

Q2 2024

Current Ratio

218.72%

Q2 2024

Total Assets

$14.85M

Q2 2024

Total Liabilities

$22.14M

Q2 2024

Book Value

-$7.284M

Q2 2024

Cash

$3.076M

Q2 2024

P/E

-0.7473

Nov 29, 2024 EST

Free Cash Flow

-$10.18M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Cost Of Revenue												$2.760M	$4.050M
Gross Profit												-$2.760M	-$4.050M
Gross Profit Margin

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007
Selling, General & Admin	$4.505M	$5.296M	$23.98M	$16.14M	$9.350M	$5.090M	$4.750M	$4.060M	$3.260M	$2.520M	$2.050M	$2.880M	$2.810M	$560.0K	$130.0K	$90.00K	$610.0K
YoY Change	-14.94%	-77.91%	48.57%	72.62%	83.69%	7.16%	17.0%	24.54%	29.37%	22.93%	-28.82%	2.49%	401.79%	330.77%	44.44%	-85.25%
% of Gross Profit
Research & Development	$5.210M	$5.765M	$8.475M	$49.58M	$67.35M	$71.72M	$18.47M	$7.220M	$7.410M	$4.950M	$4.880M	$2.760M	$770.0K	$6.690M	$3.160M	$3.140M	$4.590M
YoY Change	-9.63%	-31.98%	-82.91%	-26.38%	-6.09%	288.31%	155.82%	-2.56%	49.7%	1.43%	76.81%	258.44%	-88.49%	111.71%	0.64%	-31.59%
% of Gross Profit
Depreciation & Amortization	$514.0K	$562.0K	$2.415M	$2.440M	$1.650M	$260.0K	$440.0K	$620.0K	$630.0K	$680.0K	$710.0K	$730.0K	$610.0K	$290.0K	$260.0K	$290.0K	$290.0K
YoY Change	-8.54%	-76.73%	-1.02%	47.88%	534.62%	-40.91%	-29.03%	-1.59%	-7.35%	-4.23%	-2.74%	19.67%	110.34%	11.54%	-10.34%	0.0%
% of Gross Profit
Operating Expenses	$9.706M	$11.06M	$34.83M	-$7.330M	$78.35M	$77.07M	$23.66M	$11.90M	$11.30M	$8.140M	$7.640M	$6.370M	$4.170M	$7.540M	$3.560M	$3.520M	$5.490M
YoY Change	-12.25%	-68.24%	-575.16%	-109.36%	1.66%	225.74%	98.82%	5.31%	38.82%	6.54%	19.94%	52.76%	-44.69%	111.8%	1.14%	-35.88%
Operating Profit	$9.706M	-$11.06M	-$10.86M									-$9.130M	-$8.220M
YoY Change	-187.75%	1.83%										11.07%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007
Interest Expense	$343.0K	$5.270M	-$5.149M	-$11.79M	-$30.84M	-$10.66M	-$10.90M	$2.720M	$1.100M	$380.0K	-$400.0K	$170.0K	$570.0K	$210.0K	$30.00K	$320.0K	$1.230M
YoY Change	-93.49%	-202.35%	-56.33%	-61.77%	189.31%	-2.2%	-500.74%	147.27%	189.47%	-195.0%	-335.29%	-70.18%	171.43%	600.0%	-90.63%	-73.98%
% of Operating Profit	3.53%
Other Income/Expense, Net	$941.0K	$5.265M	$2.656M									-$370.0K	-$70.00K	-$10.00K	-$10.00K	-$10.00K	-$580.0K
YoY Change	-82.13%	98.23%										428.57%	600.0%	0.0%	0.0%	-98.28%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007
Pretax Income	-$6.500M	-$5.800M	-$39.98M	-$4.460M	-$109.2M	-$87.73M	-$34.55M	-$9.180M	-$10.20M	-$7.760M	-$8.040M	-$9.330M	-$7.720M	-$7.340M	-$3.530M	-$3.200M	-$4.840M
YoY Change	12.07%	-85.49%	796.37%	-95.92%	24.46%	153.92%	276.36%	-10.0%	31.44%	-3.48%	-13.83%	20.85%	5.18%	107.93%	10.31%	-33.88%
Income Tax											$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$6.500M	-$5.796M	-$39.98M	-$4.460M	-$109.2M	-$87.73M	-$34.55M	-$9.180M	-$10.20M	-$7.760M	-$8.040M	-$9.330M	-$7.720M	-$7.340M	-$3.530M	-$3.200M	-$4.840M
YoY Change	12.15%	-85.5%	796.37%	-95.92%	24.46%	153.92%	276.36%	-10.0%	31.44%	-3.48%	-13.83%	20.85%	5.18%	107.93%	10.31%	-33.88%
Net Earnings / Revenue
Basic Earnings Per Share	$0.00	-$0.01	-$0.02
Diluted Earnings Per Share	$0.00	-$0.01	-$70.81K	-$10.06K	-$334.3K	-$335.6K	-$171.9K	-$67.95K	-$96.66K	-$139.9K	-$170.1K	-$221.4K	-$200.1K	-$205.9K	-$131.1K	-$128.1K	-$217.1K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007
Cash & Short-Term Investments	$4.870M	$14.08M	$54.04M	$9.400M	$72.50M	$75.90M	$71.40M	$25.30M	$35.50M	$11.60M	$19.90M	$15.10M	$17.60M	$25.20M	$30.20M	$10.70M	$14.30M
YoY Change	-65.4%	-73.95%	474.85%	-87.03%	-4.48%	6.3%	182.21%	-28.73%	206.03%	-41.71%	31.79%	-14.2%	-30.16%	-16.56%	182.24%	-25.17%
Cash & Equivalents	$4.870M	$14.08M	$54.04M	$9.400M	$72.50M	$75.90M	$71.40M	$15.70M	$33.50M	$9.600M	$17.90M	$11.00M	$13.60M	$21.20M	$30.20M	$10.70M	$14.00M
Short-Term Investments							$0.00	$9.600M	$2.000M	$2.000M	$2.000M	$4.100M	$4.000M	$4.000M			$300.0K
Other Short-Term Assets	$577.0K	$295.0K										$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	95.59%
Inventory
Prepaid Expenses
Receivables												$1.500M
Other Receivables												$200.0K
Total Short-Term Assets	$5.447M	$14.37M	$55.05M	$10.60M	$73.10M	$76.80M	$75.30M	$26.10M	$36.90M	$12.70M	$20.40M	$16.80M	$20.70M	$26.10M	$31.10M	$11.30M	$15.20M
YoY Change	-62.09%	-73.9%	419.32%	-85.5%	-4.82%	1.99%	188.51%	-29.27%	190.55%	-37.75%	21.43%	-18.84%	-20.69%	-16.08%	175.22%	-25.66%
Property, Plant & Equipment	$12.03M	$12.70M	$44.11M	$45.80M	$42.10M	$28.20M	$5.500M	$1.400M	$2.000M	$2.600M	$3.300M	$3.800M	$4.200M	$2.000M	$600.0K	$700.0K	$900.0K
YoY Change	-5.29%	-71.21%	-3.7%	8.79%	49.29%	412.73%	292.86%	-30.0%	-23.08%	-21.21%	-13.16%	-9.52%	110.0%	233.33%	-14.29%	-22.22%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments							$0.00	$2.100M	$2.000M	$2.000M	$2.100M	$2.000M	$2.000M	$2.000M	$2.100M	$0.00
YoY Change							-100.0%	5.0%	0.0%	-4.76%	5.0%	0.0%	0.0%	-4.76%
Other Assets			$444.0K	$500.0K	$500.0K	$700.0K	$900.0K	$500.0K	$300.0K	$1.100M	$100.0K	$600.0K	$500.0K	$500.0K	$100.0K	$0.00	$100.0K
YoY Change			-11.2%	0.0%	-28.57%	-22.22%	80.0%	66.67%	-72.73%	1000.0%	-83.33%	20.0%	0.0%	400.0%		-100.0%
Total Long-Term Assets	$12.03M	$12.70M	$44.55M	$46.30M	$42.70M	$29.00M	$6.400M	$4.000M	$4.400M	$5.800M	$5.400M	$6.400M	$6.700M	$4.600M	$2.800M	$800.0K	$1.100M
YoY Change	-5.29%	-71.5%	-3.78%	8.43%	47.24%	353.13%	60.0%	-9.09%	-24.14%	7.41%	-15.63%	-4.48%	45.65%	64.29%	250.0%	-27.27%
Total Assets	$17.47M	$27.07M	$99.60M	$56.90M	$115.8M	$105.8M	$81.70M	$30.10M	$41.30M	$18.50M	$25.80M	$23.20M	$27.40M	$30.70M	$33.90M	$12.10M	$16.30M
YoY Change
Accounts Payable	$535.0K	$716.0K	$3.107M	$1.900M	$17.10M	$20.70M	$6.200M	$700.0K	$900.0K	$500.0K	$400.0K	$400.0K	$1.100M	$1.900M	$1.300M	$400.0K	$200.0K
YoY Change	-25.28%	-76.96%	63.53%	-88.89%	-17.39%	233.87%	785.71%	-22.22%	80.0%	25.0%	0.0%	-63.64%	-42.11%	46.15%	225.0%	100.0%
Accrued Expenses	$1.245M	$1.622M	$211.2K	$200.0K	$200.0K							$100.0K
YoY Change	-23.24%	667.96%	5.6%	0.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$60.40M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due			$773.0K	$700.0K	$700.0K
YoY Change			10.43%	0.0%
Total Short-Term Liabilities	$1.780M	$2.338M	$7.207M	$64.20M	$19.00M	$21.80M	$6.900M	$1.400M	$1.700M	$1.800M	$1.800M	$1.000M	$1.700M	$2.600M	$1.900M	$700.0K	$900.0K
YoY Change	-23.87%	-67.56%	-88.77%	237.89%	-12.84%	215.94%	392.86%	-17.65%	-5.56%	0.0%	80.0%	-41.18%	-34.62%	36.84%	171.43%	-22.22%
Long-Term Debt	$19.37M	$20.08M	$68.96M	$6.100M	$130.6M	$94.40M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	-3.56%	-70.88%	1030.56%	-95.33%	38.35%
Other Long-Term Liabilities	$893.0K	$6.407M	$95.00K	$1.200M	$31.30M	$20.90M	$18.60M	$3.100M	$6.100M	$100.0K	$100.0K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	-86.06%	6644.21%	-92.08%	-96.17%	49.76%	12.37%	500.0%	-49.18%	6000.0%	0.0%
Total Long-Term Liabilities	$20.26M	$26.49M	$69.06M	$7.300M	$161.9M	$115.3M	$18.60M	$3.100M	$6.100M	$100.0K	$100.0K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	-23.51%	-61.64%	846.01%	-95.49%	40.42%	519.89%	500.0%	-49.18%	6000.0%	0.0%
Total Liabilities	$22.04M	$28.83M	$76.27M	$71.50M	$180.8M	$137.1M	$25.40M	$4.500M	$7.800M	$1.900M	$1.800M	$1.000M	$1.700M	$2.600M	$1.900M	$700.0K	$900.0K
YoY Change	-23.54%	-62.2%	6.67%	-60.45%	31.87%	439.76%	464.44%	-42.31%	310.53%	5.56%	80.0%	-41.18%	-34.62%	36.84%	171.43%	-22.22%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021
Basic Shares Outstanding	1.563B shares	754.1M shares	564.6M shares
Diluted Shares Outstanding	1.563B shares	754.1M shares	564.6M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $2.768 Million

About Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics Ltd is a IL-based company operating in Biotechnology industry. Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The firm's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.

Industry: Biological Products, (No Diagnostic Substances) Peers: MediWound Ltd. PAINREFORM LTD. PolyPid Ltd. RedHill Biopharma Ltd.